Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focusing on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), has announced its participation in two upcoming investor conferences. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and the Cantor Global Healthcare Conference from September 17-19, 2024.
During these events, Rezolute's management team will be available for one-on-one meetings with investors. Interested parties are encouraged to contact their H.C. Wainwright and Cantor representatives to schedule meetings. This participation provides an opportunity for investors to gain insights into Rezolute's progress in addressing rare diseases, particularly its work on hypoglycemia caused by hyperinsulinism.
Rezolute, Inc. (Nasdaq: RZLT), un'azienda che opera in fase avanzata nel settore delle malattie rare, focalizzata sul miglioramento dei risultati per le persone con ipoglicemia causata da iperinsulinemia (HI), ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà al 26° Convegno Globale Annuale di Investimenti H.C. Wainwright dal 9 all'11 settembre 2024, e al Convegno Globale sulla Sanità Cantor dal 17 al 19 settembre 2024.
Durante questi eventi, il team di gestione di Rezolute sarà disponibile per incontri individuali con gli investitori. Le parti interessate sono incoraggiate a contattare i loro rappresentanti H.C. Wainwright e Cantor per programmare incontri. Questa partecipazione offre un'opportunità agli investitori di ottenere approfondimenti sui progressi di Rezolute nel trattare le malattie rare, in particolare il suo lavoro sull'ipoglicemia causata da iperinsulinemia.
Rezolute, Inc. (Nasdaq: RZLT), una empresa en etapa avanzada dedicada a enfermedades raras que se centra en mejorar los resultados para individuos con hipoglucemia causada por hiperinsulinismo (HI), ha anunciado su participación en dos próximas conferencias para inversionistas. La empresa asistirá a la 26ª Conferencia Global Anual de Inversión de H.C. Wainwright del 9 al 11 de septiembre de 2024, y a la Conferencia Global de Salud de Cantor del 17 al 19 de septiembre de 2024.
Durante estos eventos, el equipo de gestión de Rezolute estará disponible para reuniones uno a uno con los inversionistas. Se anima a las partes interesadas a contactar a sus representantes de H.C. Wainwright y Cantor para programar reuniones. Esta participación brinda a los inversionistas la oportunidad de obtener información sobre el progreso de Rezolute en el abordaje de enfermedades raras, especialmente su trabajo en la hipoglucemia causada por hiperinsulinismo.
Rezolute, Inc. (Nasdaq: RZLT)는 고인슐린혈증(HI)으로 인한 저혈당 환자의 결과 개선에 중점을 둔 후기 단계의 희귀 질환 회사로, 두 개의 예정된 투자자 회의에 참여하겠다고 발표했습니다. 회사는 2024년 9월 9일부터 11일까지 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의와 2024년 9월 17일부터 19일까지 열리는 Cantor 글로벌 헬스케어 회의에 참석할 예정입니다.
이 행사 동안 Rezolute의 경영진은 투자자들과의 개별 회의를 위해 대기하고 있습니다. 관심 있는 당사자는 H.C. Wainwright 및 Cantor 대표자에게 연락하여 회의를 예약할 것을 권장합니다. 이러한 참여는 투자자들에게 Rezolute가 희귀 질환을 다루는 과정, 특히 고인슐린혈증으로 인한 저혈당에 대한 작업에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Rezolute, Inc. (Nasdaq: RZLT), une entreprise en phase avancée spécialisée dans les maladies rares et axée sur l'amélioration des résultats pour les individus souffrant d'hypoglycémie causée par hyperinsulinisme (HI), a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise assistera à la 26ème Conférence Annuelle Mondiale sur les Investissements de H.C. Wainwright du 9 au 11 septembre 2024, et à la Conférence Mondiale sur la Santé de Cantor du 17 au 19 septembre 2024.
Au cours de ces événements, l'équipe de direction de Rezolute sera disponible pour des réunions individuelles avec les investisseurs. Il est conseillé aux parties intéressées de contacter leurs représentants H.C. Wainwright et Cantor pour planifier des réunions. Cette participation offre aux investisseurs l'opportunité d'obtenir des informations sur les avancées de Rezolute dans la lutte contre les maladies rares, en particulier son travail sur l'hypoglycémie causée par hyperinsulinisme.
Rezolute, Inc. (Nasdaq: RZLT), ein Unternehmen in der späten Phase seltener Krankheiten mit dem Fokus auf die Verbesserung der Ergebnisse für Personen mit Hypoglykämie durch Hyperinsulinismus (HI), hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 und an der Cantor Global Healthcare Conference vom 17. bis 19. September 2024 teilnehmen.
Während dieser Veranstaltungen wird das Managementteam von Rezolute für persönliche Gespräche mit Investoren zur Verfügung stehen. Interessierte Parteien werden ermutigt, ihre H.C. Wainwright- und Cantor-Vertreter zu kontaktieren, um Meetings zu vereinbaren. Diese Teilnahme bietet Investoren die Möglichkeit, Einblicke in die Fortschritte von Rezolute bei der Bekämpfung seltener Krankheiten, insbesondere in Bezug auf die Hypoglykämie durch Hyperinsulinismus, zu erhalten.
- None.
- None.
REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Event: Cantor Global Healthcare Conference
Date: September 17-19, 2024
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Cantor representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
FAQ
What investor conferences will Rezolute (RZLT) attend in September 2024?
How can investors meet with Rezolute (RZLT) management at the upcoming conferences?
What is Rezolute's (RZLT) primary focus in rare disease treatment?
When will the Cantor Global Healthcare Conference that Rezolute (RZLT) is attending take place?
